New therapeutic agents in gastrointestinal stromal tumours

被引：17

作者：

Falkenhorst, Johanna ^{[1
]}

Hamacher, Rainer ^{[1
]}

Bauer, Sebastian ^{[1
]}

机构：

[1] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Sarcoma Ctr, Essen, Germany

来源：

CURRENT OPINION IN ONCOLOGY | 2019年 / 31卷 / 04期

关键词：

activation loop mutations; gastrointestinal stromal tumours; PDGFRA D842 V; type III inhibitor; tyrosine kinase inhibitors; SWITCH-CONTROL INHIBITOR; WNT/BETA-CATENIN; KIT; IMATINIB; MUTATIONS; RESISTANT; MULTICENTER; DOVITINIB; DCC-2618; SURVIVAL;

D O I：

10.1097/CCO.0000000000000549

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of review The aim of this study was to provide an update on the most recent developments regarding systemic treatments in the various molecular subtypes of gastrointestinal stromal tumour (GIST). Recent findings Several novel direct inhibitors of KIT and PDGFRA have entered the advanced clinical development in later treatment lines based on promising early clinical trial experience. Both avapritinib and ripretinib are more potent and more specific against various KIT and PDGFRA mutations. For patients with PDGFRA D842V mutations, the next generation of drugs may become the first active treatment options. Comprehensive molecular testing of KIT/PDGFRA-wildtype GIST may unmask clinically relevant targets, including NTRK fusions. Summary: The treatment landscape in GIST is expected to undergo a profound transformation with more potent drugs currently in late-stage clinical development.

引用

页码：322 / 328

页数：7

共 53 条

[1] Genomic analysis of prostate cancer [J].

Barnett, Christine M. ;

Heinrich, Michael C. ;

Nelson, Dylan A. ;

Lim, Jeong Youn ;

Beadling, Carol ;

Warrick, Andrea ;

Neff, Tanaya ;

Thomas, George ;

Garzotto, Mark ;

Higano, Celestia S. ;

Beer, Tomasz M. ;

Qian, David Z. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)

[2] "Wnt/β-Catenin in GIST"-Letter [J].

Bertucci, Francois ;

Finetti, Pascal ;

De Nonneville, Alexandre ;

Birnbaum, Daniel .

MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01) :327-328

[3]

BLAY J-Y, 2017, J CLIN ONCOL S15, V35

[4] Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo [J].

Boichuk, Sergei ;

Galembikova, Aigul ;

Dunaev, Pavel ;

Micheeva, Ekaterina ;

Valeeva, Elena ;

Novikova, Maria ;

Khromova, Natalya ;

Kopnin, Pavel .

MOLECULES, 2018, 23 (10)

[5] Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor [J].

Bosbach, Benedikt ;

Rossi, Ferdinand ;

Yozgat, Yasemin ;

Loo, Jennifer ;

Zhang, Jennifer Q. ;

Berrozpe, Georgina ;

Warpinski, Katherine ;

Ehlers, Imke ;

Veach, Darren ;

Kwok, Andrew ;

Manova, Katia ;

Antonescu, Cristina R. ;

DeMatteo, Ronald P. ;

Besmer, Peter .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (40) :E8448-E8457

[6] Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg 68, 2018) [J].

Casali, P. G. ;

Abecassis, N. ;

Aro, H. T. ;

Bauer, S. ;

Biagini, R. ;

Bielack, S. ;

Bonvalot, S. ;

Boukovinas, I. ;

Bovee, J. V. M. G. ;

Brodowicz, T. ;

Broto, J. M. ;

Buonadonna, A. ;

De Alava, E. ;

Tos, A. P. Dei ;

Del Muro, X. G. ;

Dileo, P. ;

Eriksson, M. ;

Fedenko, A. ;

Ferraresi, V. ;

Ferrari, A. ;

Ferrari, S. ;

Frezza, A. M. ;

Gasperoni, S. ;

Gelderblom, H. ;

Gil, T. ;

Grignani, G. ;

Gronchi, A. ;

Haas, R. L. ;

Hassan, B. ;

Hohenberger, P. ;

Issels, R. ;

Joensuu, H. ;

Jones, R. L. ;

Judson, I. ;

Jutte, P. ;

Kaal, S. ;

Kasper, B. ;

Kopeckova, K. ;

Krakorova, D. A. ;

Le Cesne, A. ;

Lugowska, I. ;

Merimsky, O. ;

Montemurro, M. ;

Pantaleo, M. A. ;

Piana, R. ;

Picci, P. ;

Piperno-Neumann, S. ;

Pousa, A. L. ;

Reichardt, P. ;

Robinson, M. H. .

ANNALS OF ONCOLOGY, 2018, 29 :267-267

[7] Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels [J].

Casali, Paolo G. ;

Zalcberg, John ;

Le Cesne, Axel ;

Reichardt, Peter ;

Blay, Jean-Yves ;

Lindner, Lars H. ;

Judson, Ian R. ;

Schoffski, Patrick ;

Leyvraz, Serge ;

Italiano, Antoine ;

Grunwald, Viktor ;

Pousa, Antonio Lopez ;

Kotasek, Dusan ;

Sleijfer, Stefan ;

Kerst, Jan M. ;

Rutkowski, Piotr ;

Fumagalli, Elena ;

Hogendoorn, Pancras ;

Litiere, Saskia ;

Marreaud, Sandrine ;

van der Graaf, Winette ;

Gronchi, Alessandro ;

Verweij, Jaap .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (15) :1713-+

[8] Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era [J].

Cassier, Philippe A. ;

Fumagalli, Elena ;

Rutkowski, Piotr ;

Schoeffski, Patrick ;

Van Glabbeke, Martine ;

Debiec-Rychter, Maria ;

Emile, Jean-Francois ;

Duffaud, Florence ;

Martin-Broto, Javier ;

Landi, Bruno ;

Adenis, Antoine ;

Bertucci, Francois ;

Bompas, Emmanuelle ;

Bouche, Olivier ;

Leyvraz, Serge ;

Judson, Ian ;

Verweij, Jaap ;

Casali, Paolo ;

Blay, Jean-Yves ;

Hohenberger, Peter .

CLINICAL CANCER RESEARCH, 2012, 18 (16) :4458-4464

[9] Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors [J].

Chen, Weicai ;

Kuang, Ye ;

Qiu, Hai-Bo ;

Cao, Zhifa ;

Tu, Yuqing ;

Sheng, Qing ;

Eilers, Grant ;

He, Quan ;

Li, Hai-Long ;

Zhu, Meijun ;

Wang, Yuexiang ;

Zhang, Rongqing ;

Wu, Yeqing ;

Meng, Fanguo ;

Fletcher, Jonathan A. ;

Ou, Wen-Bin .

CANCER RESEARCH, 2017, 77 (18) :5107-5117

[10]

Colwell J, 2017, CANCER DISCOV, V7, P121, DOI 10.1158/2159-8290.CD-NB2016-161

← 1 2 3 4 5 6 →